194 related articles for article (PubMed ID: 25522335)
21. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
23. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
[TBL] [Abstract][Full Text] [Related]
25. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
[No Abstract] [Full Text] [Related]
26. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide.
Haapala K; Hyytinen ER; Roiha M; Laurila M; Rantala I; Helin HJ; Koivisto PA
Lab Invest; 2001 Dec; 81(12):1647-51. PubMed ID: 11742035
[TBL] [Abstract][Full Text] [Related]
27. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.
Lee GT; Kang DI; Ha YS; Jung YS; Chung J; Min K; Kim TH; Moon KH; Chung JM; Lee DH; Kim WJ; Kim IY
Br J Cancer; 2014 Mar; 110(6):1634-44. PubMed ID: 24518599
[TBL] [Abstract][Full Text] [Related]
29. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
30. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.
Cros J; Sbidian E; Hans S; Roussel H; Scotte F; Tartour E; Brasnu D; Laurent-Puig P; Bruneval P; Blons H; Badoual C
Ann Oncol; 2013 Oct; 24(10):2624-2629. PubMed ID: 23933559
[TBL] [Abstract][Full Text] [Related]
31. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
[TBL] [Abstract][Full Text] [Related]
32. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
33. Predictors of cervical lymph node metastasis in salivary gland cancer.
Ettl T; Gosau M; Brockhoff G; Schwarz-Furlan S; Agaimy A; Reichert TE; Rohrmeier C; Zenk J; Iro H
Head Neck; 2014 Apr; 36(4):517-23. PubMed ID: 23780687
[TBL] [Abstract][Full Text] [Related]
34. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.
Ach T; Zeitler K; Schwarz-Furlan S; Baader K; Agaimy A; Rohrmeier C; Zenk J; Gosau M; Reichert TE; Brockhoff G; Ettl T
Virchows Arch; 2013 Jan; 462(1):65-72. PubMed ID: 23242174
[TBL] [Abstract][Full Text] [Related]
35. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Wang LG; Mencher SK; McCarron JP; Ferrari AC
Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
[TBL] [Abstract][Full Text] [Related]
36. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
[TBL] [Abstract][Full Text] [Related]
37. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
38. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
39. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
